Unichem Labs. Q1 FY27 Results (NSE: UNICHEMLAB)
Signal: Loss reversed
The read
The trajectory inflected positively after two quarters of consolidated losses: revenue reached ₹632.62 crore, +20.1% YoY, EBITDA margin rebounded to 13.5% from 4.3%, and PAT turned to ₹41.47 crore, but the sustainability test is whether operating recovery persists without relying on ₹15.61 crore of other income and with standalone revenue still down 4.7%.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹632.62 Cr | 20.1% | +10.0% |
| EBIT | ₹55.61 Cr | N/A | |
| Net profit | ₹41.47 Cr | N/A | |
| EPS | ₹6.61 | N/A | |
| EBIT margin | 13.5% |
P&L walk
Consolidated revenue increased to ₹632.62 crore, +20.1% YoY and +10.0% QoQ, while EBITDA margin expanded to 13.5% from 4.3% and PAT turned positive at ₹41.47 crore from a ₹10.47 crore loss; the recovery is operationally meaningful but other income of ₹15.61 crore represented 31.9% of PBT.
Segments
The company reports a single Pharmaceuticals segment, but the consolidated-standalone gap is material: consolidated revenue was ₹632.62 crore versus standalone revenue of ₹366.27 crore, while consolidated PAT was ₹41.47 crore versus standalone PAT of ₹5.53 crore, indicating overseas subsidiaries drove the quarter.
Key positives
- Consolidated revenue of ₹632.62 crore grew 20.1% YoY, reversing the -2.3% and -2.0% YoY declines recorded in Q3FY26 and Q4FY26.
- EBITDA increased to ₹85.55 crore, +191.9% YoY, and EBITDA margin expanded 920bps YoY to 13.5%; employee costs fell 3.8% YoY and depreciation fell 5.8% YoY.
- Standalone gross margin expanded approximately 510bps YoY to 57.8% despite standalone revenue declining 4.7%, while standalone finance costs fell 33.2% YoY to ₹1.29 crore.
- PAT and EPS both turned positive from YoY losses, with consolidated PAT at ₹41.47 crore and EPS at ₹6.61.
Key concerns
- Standalone revenue declined 4.7% YoY to ₹366.27 crore, so the consolidated recovery is materially dependent on overseas subsidiaries rather than the parent business.
- Consolidated other income of ₹15.61 crore represented 31.9% of PBT, while standalone other income of ₹16.72 crore represented 226.6% of standalone PBT; reported profit quality therefore requires normalization.
- The filing does not disclose product, geography, volume, price/mix, approvals or R&D metrics, limiting visibility into the operating drivers of the revenue and margin rebound.
- Standalone operating profit before exceptional items was only ₹7.38 crore, indicating that the ₹5.53 crore standalone PAT recovery remains low-base and fragile.
Earnings quality: includes non-operating other income
Research and educational content only. Not investment advice.